Australia Anti-vascular Endothelial Growth Factor Therapeutics Market Size & Outlook
Australia anti-vascular endothelial growth factor therapeutics market, 2018-2030 (US$M)
Related Markets
Australia anti-vascular endothelial growth factor therapeutics market highlights
- The Australia anti-vascular endothelial growth factor therapeutics market generated a revenue of USD 71.6 million in 2024 and is expected to reach USD 41.3 million by 2030.
- The Australia market is expected to grow at a CAGR of -9.3% from 2025 to 2030.
- In terms of segment, eylea was the largest revenue generating product in 2024.
- Vabysmo is the most lucrative product segment registering the fastest growth during the forecast period.
Anti-vascular endothelial growth factor therapeutics market data book summary
| Market revenue in 2024 | USD 71.6 million |
| Market revenue in 2030 | USD 41.3 million |
| Growth rate | -9.3% (CAGR from 2025 to 2030) |
| Largest segment | Eylea |
| Fastest growing segment | Vabysmo |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
| Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, Australia accounted for 0.5% of the global anti-vascular endothelial growth factor therapeutics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan anti-vascular endothelial growth factor therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 95.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-Vascular Endothelial Growth Factor Therapeutics Market Scope
Anti-Vascular Endothelial Growth Factor Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia anti-vascular endothelial growth factor therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 54.89% in 2024. Horizon Databook has segmented the Australia anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
Australia is expected to exhibit a significant CAGR over the forecast period, due to increasing market opportunities and growing prevalence of related diseases. In January 2020, Novartis AG received TGA’s approval of Beovu (Brolucizumab) for the treatment of wet AMD to address the unmet medical needs of the population.
Furthermore, local players are focusing on development of novel anti-VEGF therapies for treatment of progressive retinal diseases. For instance, in August 2020, Opthea announced the completion of meetings with the U.S. FDA and EMA after phase 2 clinical trial for the initiation of phase 3 clinical trial on OPT-302 for treating wet AMD.
The Pharmaceutical Benefits Scheme (PBS) in Australia has provisions for coverage at government treatment centers, extended to patients that meet the eligibility criteria for ophthalmic diseases. The inclusions ranibizumab and aflibercept in PBS can support the adoption of anti-VEGF therapeutics for the treatment of nAMD.
Reasons to subscribe to Australia anti-vascular endothelial growth factor therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia anti-vascular endothelial growth factor therapeutics market databook
-
Our clientele includes a mix of anti-vascular endothelial growth factor therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Australia anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia anti-vascular endothelial growth factor therapeutics market size, by product, 2018-2030 (US$M)
Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
